| Differential regulation in the avian song control circuit of an mRNA predicting a highly conserved protein related to protein kinase C and the bcr oncogene. | None |
| Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. | None |
| Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays. | None |
| BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. | None |
| Osteopontin is upregulated by BCR-ABL. | None |
| Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. | None |
| A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. | None |
| Identification of the CEBPB gene as a target of translational regulation in myeloid precursor cells transformed by the BCR/ABL oncogene. | None |
| Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells. | None |
| BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. | None |
| Ubp43 deficiency increases the resistance to oncogenic transformation by BCR-ABL | None |
| Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein. | None |
| High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. | None |
| Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. | None |
| Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. | None |
| Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects. | None |
| Bcr-Abl oncoprotein requires the IL-3 receptor/Jak2/Stat5 pathways for oncogenic transformation of NIH 3T3 fibroblasts. | None |
| These results demonstrate that allele-specific changes in gene expression, with selective, progressive silencing of the wild-type ABL1 allele in favor of the oncogenic BCR-ABL1 allele occur in CML patients with therapy-resistant disease. | None |
| Bcr-Abl induces autocrine IGF-1 signaling. | None |
| Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. | None |